

## **Professor Pellicciari awarded by President Mattarella with the Bronze Medal of Merit for Public Health**

Solomeo-Corciano (PG), Italy, April 10 – Tes Pharma srl is pleased to announce that our esteemed Prof. Roberto Pellicciari, Founder and Chief Scientific Advisor of Tes Pharma, has been awarded by President Mattarella, with the ‘Bronze Medal for Public Health Merit’ in recognition of his exceptional contribution to public health and community well-being. Prof. Pellicciari, who founded Tes Pharma in 2011, has demonstrated extraordinary commitment to promoting public health and has distinguished himself by the discovery of ‘obeticholic acid’ – Ocaliva, a drug that has changed the therapeutic approach to primary biliary cholangitis, a rare liver disease.

The award ceremony was held on Monday, April 7, 2025, at the Quirinale Palace in Rome, in the presence of prominent figures from the healthcare, academic, and institutional sectors. During the event, Prof. Pellicciari has received the medal from President of the Italian Republic, Sergio Mattarella, and the Minister of Health, Orazio Schillaci.

*"We are extremely proud to see our partner and founder, Prof. Roberto Pellicciari, receive this recognition" said **Luca Benatti**, Chief Executive Officer of Tes Pharma . "His work has had a profound and lasting impact on our community and, with his role in Tes Pharma is contributing to the discovery and development of other bile acid derivatives now in clinical development with partner Alfasigma and to other first in-class proprietary compounds for other diseases with high unmet need."*

### **About Tes Pharma**

Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept for the discovery and development of bile acid derivatives for the treatment of liver disease. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol-associated hepatitis (sAH). Separate from the collaboration with Intercept, Tes Pharma is also developing TES-AKI-01 and TES-ONC-07, two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, that are entering IND-enabling studies. Also, Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery. For more information, please visit [www.tespharma.com](http://www.tespharma.com) or connect with the Company on [LinkedIn](#)

For further information, please contact:

Sara Malincarne  
smalincarne@tespharma.com  
[www.tespharma.com](http://www.tespharma.com)